Generali Asset Management SPA SGR Lowers Stock Position in Solventum Corporation $SOLV

Key Points

• Generali Asset Management SPA SGR has reduced its stake in Solventum Corporation by 58%, leaving it with 4,619 shares valued at approximately $350,000.
• Several institutional investors, including Independent Franchise Partners LLP and Davis Selected Advisers, have increased their holdings in Solventum, indicating a diverse range of investor interest in the company.
• Research firms have varied perspectives on Solventum stock, with Zacks Research upgrading it to a "strong-buy" rating while others maintain "hold" or "buy" ratings, suggesting mixed market sentiment.

Generali Asset Management SPA SGR reduced its stake in Solventum Corporation (NYSE:SOLV - Free Report) by 58.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,619 shares of the company's stock after selling 6,369 shares during the quarter. Generali Asset Management SPA SGR's holdings in Solventum were worth $350,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Independent Franchise Partners LLP raised its stake in Solventum by 263.1% in the first quarter. Independent Franchise Partners LLP now owns 5,820,724 shares of the company's stock valued at $442,608,000 after purchasing an additional 4,217,570 shares in the last quarter. Davis Selected Advisers raised its stake in shares of Solventum by 0.8% during the first quarter. Davis Selected Advisers now owns 5,288,138 shares of the company's stock worth $402,110,000 after acquiring an additional 41,524 shares in the last quarter. Boston Partners raised its stake in shares of Solventum by 101.3% during the first quarter. Boston Partners now owns 3,361,973 shares of the company's stock worth $255,554,000 after acquiring an additional 1,691,565 shares in the last quarter. Northern Trust Corp raised its stake in shares of Solventum by 3.3% during the first quarter. Northern Trust Corp now owns 1,807,674 shares of the company's stock worth $137,456,000 after acquiring an additional 58,373 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Solventum by 2.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,173,960 shares of the company's stock worth $89,268,000 after acquiring an additional 24,762 shares in the last quarter.

Analysts Set New Price Targets

Several research firms have commented on SOLV. Zacks Research raised shares of Solventum from a "hold" rating to a "strong-buy" rating in a research note on Monday, September 15th. Wall Street Zen downgraded shares of Solventum from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, September 9th. Wells Fargo & Company lifted their price target on shares of Solventum from $79.00 to $82.00 and gave the stock an "equal weight" rating in a research note on Monday, September 15th. Jefferies Financial Group assumed coverage on shares of Solventum in a research note on Thursday, September 11th. They set a "hold" rating and a $80.00 price target on the stock. Finally, UBS Group assumed coverage on shares of Solventum in a research note on Wednesday, October 1st. They issued a "neutral" rating and a $77.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $84.89.

Solventum Stock Up 0.9%

Shares of NYSE SOLV opened at $72.11 on Friday. The company has a quick ratio of 0.86, a current ratio of 1.22 and a debt-to-equity ratio of 2.14. Solventum Corporation has a 52 week low of $60.70 and a 52 week high of $85.92. The firm's fifty day moving average is $72.63 and its 200 day moving average is $71.95. The company has a market cap of $12.50 billion, a price-to-earnings ratio of 33.38, a PEG ratio of 2.94 and a beta of 0.50.

Solventum (NYSE:SOLV - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, topping the consensus estimate of $1.45 by $0.24. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The company had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.12 billion. During the same period in the previous year, the firm earned $1.56 earnings per share. The firm's revenue for the quarter was up 3.8% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, equities research analysts expect that Solventum Corporation will post 6.58 earnings per share for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.